On July 14, 2025, Adial Pharmaceuticals announced that Nasdaq confirmed its compliance with listing rules following a $3.6 million capital raise that addressed previous equity shortfalls. The company’s stockholders’ equity is now reported at $2,126,662 as of March 31, 2025, which was below the required $2,500,000.